Holy Name Medical Center

Summary

Holy Name Medical Center is a medical facility located in Teaneck, New Jersey. This center is recognized for care of Breast Cancer, Ovarian Cancer, Peripheral Artery Disease, Fallopian Tube Cancer, Multiple Sclerosis and other specialties. Holy Name Medical Center is involved with conducting 140 clinical trials across 191 conditions. There are 13 research doctors associated with this hospital, such as John Rundback, MD, Yadyra Rivera, Sharyn Lewin, MD, and Jason C. Lee.

Top PIs

Clinical Trials running at Holy Name Medical Center

Ovarian Cancer

Breast Cancer

Fallopian Tube Cancer

Pancreatic Cancer

Pancreatic Carcinoma

Cervical Cancer

Breast cancer

Prostate Cancer

Non-Small Cell Lung Cancer

Endometrial Cancer

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria

LY4170156

for Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Recruiting

2 awards

Phase 3

4 criteria